Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

371.75 +1.92 (+0.52%)
Streaming Delayed Price Updated: 12:27 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Argenx Se ADR

argenx Announces Annual General Meeting of Shareholders on May 2, 2023
From argenx SE
Via Globe NewsWire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
From argenx SE
Via Globe NewsWire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via Globe NewsWire
argenx Announces Planned Transition of Chief Operating Officer
From argenx SE
Via Globe NewsWire
argenx Appoints Steve Krognes to Board of Directors
From argenx SE
Via Globe NewsWire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via Globe NewsWire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
From argenx SE
Via Globe NewsWire
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via Globe NewsWire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via Globe NewsWire
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via Globe NewsWire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via Globe NewsWire
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via Globe NewsWire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via Globe NewsWire
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via Globe NewsWire
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via Globe NewsWire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via Globe NewsWire
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
From argenx SE
Via Globe NewsWire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
From argenx SE
Via Globe NewsWire
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
From argenx SE
Via Globe NewsWire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via Globe NewsWire
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
From argenx
Via Business Wire
argenx Highlights Strategic Priorities for 2022
From argenx
Via Business Wire
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.